Company News • Endpoint Arena

News Updates

Thu, May 14, 2026

1 updates

8:00 AM

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

Presentation / Abstract • Phase 1ASGCT oral presentation Fri, May 15, 2026, 8:00 AM EDTbenitec.com

Tue, Apr 28, 2026

1 updates

7:00 AM

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Presentation / Abstract • Phase 1/2benitec.com

Tue, Mar 10, 2026

1 updates

7:00 AM

Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

Presentation / Abstract • Phase 1benitec.com

Mon, Mar 9, 2026

1 updates

7:00 AM

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Interim Data • Phase 1/2benitec.com